In the current AI boom, companies are raising subsequent funding rounds at the same high revenue multiples as previous ones, months apart. This is because growth rates aren't decelerating as expected, challenging the wisdom that valuation multiples must compress as revenue scales.

A fast-growing, break-even SaaS is often more valuable than a slow-growing, highly profitable one. Buyers, especially private equity, prioritize growth because it's the clearest path to achieving their 3-5x return target. They can optimize for profit later; restarting growth is significantly harder.

Brex's acquisition creates a complex challenge for its rival, Ramp. While validating Ramp's market leadership, it simultaneously establishes a low public M&A valuation multiple (7x revenue vs. Ramp's 30x), and introduces a powerful competitor with a structural cost advantage via the Discover network.

Mercor's Series B valuation of $2B on $20M ARR (a 100x multiple) seemed high but was justified by their track record of hypergrowth. They had consistently grown 50% month-over-month and accurately projected massive future revenue milestones, giving investors confidence in a valuation that priced in future performance.

The bar for early-stage funding has shifted dramatically. While 3x year-over-year growth was once impressive, investors now seek unprecedented acceleration, often modeling companies that go from $1M to $100M ARR in a year. This leaves many solid, compounding businesses unable to secure traditional venture capital.

For startups experiencing hyper-growth, the optimal strategy is to raise capital aggressively and frequently—even multiple times a year—regardless of current cash reserves. This builds a war chest, solidifies a high valuation based on momentum, and effectively starves less explosive competitors of investor attention and capital.

Public market investors systematically underestimate sustained high growth (e.g., 60%+), defaulting to models that assume rapid deceleration. This creates an opportunity for private investors with longer time horizons to more accurately value these companies.

A sharply increasing valuation isn't a sign of overpricing; it's often a sign of underpricing. Investors anchor to previous rounds instead of the company's current reality and future potential, causing even a 2x up-round to be less than the 4x it might deserve.

Venture capitalists may value a solid $15M revenue company at zero. Their model is not built on backing good businesses, but on funding 'upside options'—companies with the potential for explosive, outlier growth, even if they are currently unprofitable.